RMTI · XBRL financial data

Rockwell Medical financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RMTI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cost of goods and services sold	59,472	64,351	68,733	74,908	84,005	57,563
Gross profit	2,725	(2,420)	4,077	8,704	17,484	11,695
Research and development	—	—	—	1,107	19	0
General and administrative	16,182	15,348	15,644	12,142	14,108	14,032
Operating income (loss)	(28,420)	(30,336)	(16,780)	(6,670)	608	(4,691)
Interest income	238	22	33	211	—	—
Interest expense	1,879	2,360	1,936	2,301	1,254	1,124
Other income (expense)	(2,470)	(2,338)	(1,899)	(1,769)	(1,088)	(623)
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(30,890)	(32,674)	(18,679)	(8,439)	(480)	(5,314)
Earnings per share, basic‡ USD per share	(4.15)	(3.54)	(0.17)	(0.37)	(0.03)	(0.15)
Earnings per share, diluted‡ USD per share	(4.15)	(3.54)	(0.17)	(0.37)	(0.03)	(0.15)
Weighted average shares, basic‡ thousands of shares	7,479	9,276	108,427	23,323	31,059	35,974
Weighted average shares, diluted‡ thousands of shares	7,479	9,276	108,427	23,323	31,059	35,974

‡ Per-share figures and share counts are adjusted for the 1-for-11.11111111111111 stock split (May 2022); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (May 2022); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 10.989010989010989-for-1 stock split (May 2022); filings made before it reported them unadjusted.
† Share count changed about 15x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (RMTI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	48,682	13,280	10,102	8,983	15,662	10,711
Marketable securities	9,997	9,158	11,390	1,952	5,940	14,286
Accounts receivable	4,171	5,913	6,259	10,901	8,291	8,143
Inventory	3,913	4,076	5,814	5,871	5,778	3,424
Prepaid and other current assets	2,706	2,861	1,745	1,063	1,359	1,599
Total current assets	69,469	35,288	35,310	28,770	37,030	38,163
Property and equipment, net	2,642	2,486	2,194	6,402	5,785	4,629
Right-of-use asset	2,911	7,700	3,943	2,713	3,215	2,569
Goodwill	921	921	921	921	921	921
Total assets	77,748	48,574	46,635	52,173	59,208	57,145
Accounts payable	4,155	3,739	4,053	4,516	2,869	1,999
Accrued liabilities	5,013	5,090	7,702	7,149	6,275	4,337
Current portion of long-term debt	0	7,381	1,631	0	—	0
Total current liabilities	12,793	20,966	17,691	16,637	14,091	9,580
Long-term debt	20,949	13,186	7,555	8,293	8,472	8,826
Lease liability, non-current	1,821	—	2,581	1,433	1,699	1,454
Total liabilities	43,578	46,039	32,529	30,882	26,622	20,164
Accumulated deficit	(337,406)	(370,080)	(388,759)	(397,198)	(397,678)	(402,992)
Total stockholders' equity	34,170	2,535	14,106	21,291	32,586	36,981
Total liabilities and equity	77,748	48,574	46,635	52,173	59,208	57,145
Common shares outstanding (cover page)‡ thousands of shares	9,256	9,295	137,941	29,335	34,057	39,405

‡ Per-share figures and share counts are adjusted for the 1-for-11.11111111111111 stock split (May 2022); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (May 2022); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 10.989010989010989-for-1 stock split (May 2022); filings made before it reported them unadjusted.
† Share count changed about 15x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (RMTI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(30,890)	(32,674)	(18,679)	(8,439)	(480)	(5,314)
Stock-based compensation	475	943	315	932	1,292	1,816
Depreciation and amortization	834	668	576	1,444	2,180	2,192
Net cash from operating activities	(29,641)	(33,534)	(17,414)	(9,412)	4,202	(659)
Net cash from investing activities	3,212	311	(2,396)	(3,045)	(4,866)	(8,544)
Proceeds from issuing common stock	—	—	15,016	14,861	10,181	7,816
Proceeds from long-term debt	22,500	0	—	—	—	—
Net cash from financing activities	63,316	(2,179)	16,632	11,342	7,348	4,252
Net change in cash	36,887	(35,402)	(3,178)	(1,119)	6,679	(4,951)

† Share count changed about 15x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Rockwell Medical	10,519	not reported	2,080*	4.0M	—	Q2 FY26 10-QJun 30, 2026
Champions Oncology	4,358	15,232	(492)	13.9M	8.0 quarters	Q1 FY27 10-QJul 31, 2026
OnKure Therapeutics	166,502	not reported	(10,354)*	40.5M	17.0 quarters	Q2 FY26 10-QJun 30, 2026
Cumberland Pharmaceuticals	3,862	166	169*	15.0M	—	Q2 FY26 10-QJun 30, 2026
ProMIS Neurosciences	53,429	not reported	(10,385)*	9.0M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Tempest Therapeutics	779	not reported	(2,779)*	16.0M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Provectus Biopharmaceuticals	1,157	not reported	(358)*	420.3M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Outlook Therapeutics	11,242	not reported	(21,011)*	243.4M	0.5 quarters	Q3 FY26 10-QJun 30, 2026
Yarrow Bioscience	22,925	97	(1,992)*	2.7M	11.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.